Medical costs associated with use of systemic therapy in adults with colorectal cancer

Brian S. Seal, Sean D. Sullivan, Scott Ramsey, Kenneth M Shermock, Jinma Ren, Charlie Kreilick, Susan H Foltz Boklage, Satish Valluri, Syam Sarma, Carl V. Asche

Research output: Contribution to journalArticle

Abstract

Background: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). Objective: To identify the patient-related and clinical and treatmentrelated factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. Methods: A longitudinal, retrospective analysis was employed to estimate costs and determinants of CRC treatment in a U.S. claims database for health care services used by commercial patients aged 18 to 64 years, who were diagnosed with CRC between January 1, 2005, and June 30, 2009. Generalized linear regression modeling was used to estimate the influence of demographic, clinical, and treatment factors on medical expenditures. Results: Among the 5,160 patients newly diagnosed with CRC, 99.6% of patients had chemotherapy; 32.6% had biologics; and 85.6% had other pharmaceuticals (excluding the chemotherapy and biologics of interest). The average annualized per patient cost of CRC treatment was $97,400 and consisted of chemotherapy ($17,500), biologics ($30,400), other pharmaceuticals ($2,300), inpatient treatment ($26,300), and outpatient treatment ($42,900). From first line only, first and second lines only, and third+ lines, the cost per patient was $70,500, $100,100, and $152,900, respectively. After adjusting for health care inflation, the average treatment cost of CRC patients increased by 73% from 2005 to 2009. Adjusted analyses showed that the higher medical cost for CRC patients was associated with use of new regimens, metastasis, comorbidities, surgery, radiation, insurance plan, age, sex, and region. Conclusion: The health care cost of CRC treatment is increasing significantly over time, which is most likely caused by the use of new regimens, higher chances of surgery and radiation, and occurrence of various comorbidities and metastatic diseases due to increasing survival time.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalJournal of Managed Care Pharmacy
Volume19
Issue number6
StatePublished - 2013

Fingerprint

Colorectal Neoplasms
Chemotherapy
Health care
Costs and Cost Analysis
Oncology
Biological Products
Costs
Surgery
Drug Therapy
Therapeutics
Health Expenditures
Delivery of Health Care
Radiation
Health Care Costs
Comorbidity
Cytotoxins
Insurance
Linear regression
Pharmaceutical Preparations
Biological Therapy

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy

Cite this

Seal, B. S., Sullivan, S. D., Ramsey, S., Shermock, K. M., Ren, J., Kreilick, C., ... Asche, C. V. (2013). Medical costs associated with use of systemic therapy in adults with colorectal cancer. Journal of Managed Care Pharmacy, 19(6), 461-467.

Medical costs associated with use of systemic therapy in adults with colorectal cancer. / Seal, Brian S.; Sullivan, Sean D.; Ramsey, Scott; Shermock, Kenneth M; Ren, Jinma; Kreilick, Charlie; Boklage, Susan H Foltz; Valluri, Satish; Sarma, Syam; Asche, Carl V.

In: Journal of Managed Care Pharmacy, Vol. 19, No. 6, 2013, p. 461-467.

Research output: Contribution to journalArticle

Seal, BS, Sullivan, SD, Ramsey, S, Shermock, KM, Ren, J, Kreilick, C, Boklage, SHF, Valluri, S, Sarma, S & Asche, CV 2013, 'Medical costs associated with use of systemic therapy in adults with colorectal cancer', Journal of Managed Care Pharmacy, vol. 19, no. 6, pp. 461-467.
Seal, Brian S. ; Sullivan, Sean D. ; Ramsey, Scott ; Shermock, Kenneth M ; Ren, Jinma ; Kreilick, Charlie ; Boklage, Susan H Foltz ; Valluri, Satish ; Sarma, Syam ; Asche, Carl V. / Medical costs associated with use of systemic therapy in adults with colorectal cancer. In: Journal of Managed Care Pharmacy. 2013 ; Vol. 19, No. 6. pp. 461-467.
@article{d367d87e54534de588898594ea6dd4dd,
title = "Medical costs associated with use of systemic therapy in adults with colorectal cancer",
abstract = "Background: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). Objective: To identify the patient-related and clinical and treatmentrelated factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. Methods: A longitudinal, retrospective analysis was employed to estimate costs and determinants of CRC treatment in a U.S. claims database for health care services used by commercial patients aged 18 to 64 years, who were diagnosed with CRC between January 1, 2005, and June 30, 2009. Generalized linear regression modeling was used to estimate the influence of demographic, clinical, and treatment factors on medical expenditures. Results: Among the 5,160 patients newly diagnosed with CRC, 99.6{\%} of patients had chemotherapy; 32.6{\%} had biologics; and 85.6{\%} had other pharmaceuticals (excluding the chemotherapy and biologics of interest). The average annualized per patient cost of CRC treatment was $97,400 and consisted of chemotherapy ($17,500), biologics ($30,400), other pharmaceuticals ($2,300), inpatient treatment ($26,300), and outpatient treatment ($42,900). From first line only, first and second lines only, and third+ lines, the cost per patient was $70,500, $100,100, and $152,900, respectively. After adjusting for health care inflation, the average treatment cost of CRC patients increased by 73{\%} from 2005 to 2009. Adjusted analyses showed that the higher medical cost for CRC patients was associated with use of new regimens, metastasis, comorbidities, surgery, radiation, insurance plan, age, sex, and region. Conclusion: The health care cost of CRC treatment is increasing significantly over time, which is most likely caused by the use of new regimens, higher chances of surgery and radiation, and occurrence of various comorbidities and metastatic diseases due to increasing survival time.",
author = "Seal, {Brian S.} and Sullivan, {Sean D.} and Scott Ramsey and Shermock, {Kenneth M} and Jinma Ren and Charlie Kreilick and Boklage, {Susan H Foltz} and Satish Valluri and Syam Sarma and Asche, {Carl V.}",
year = "2013",
language = "English (US)",
volume = "19",
pages = "461--467",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "6",

}

TY - JOUR

T1 - Medical costs associated with use of systemic therapy in adults with colorectal cancer

AU - Seal, Brian S.

AU - Sullivan, Sean D.

AU - Ramsey, Scott

AU - Shermock, Kenneth M

AU - Ren, Jinma

AU - Kreilick, Charlie

AU - Boklage, Susan H Foltz

AU - Valluri, Satish

AU - Sarma, Syam

AU - Asche, Carl V.

PY - 2013

Y1 - 2013

N2 - Background: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). Objective: To identify the patient-related and clinical and treatmentrelated factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. Methods: A longitudinal, retrospective analysis was employed to estimate costs and determinants of CRC treatment in a U.S. claims database for health care services used by commercial patients aged 18 to 64 years, who were diagnosed with CRC between January 1, 2005, and June 30, 2009. Generalized linear regression modeling was used to estimate the influence of demographic, clinical, and treatment factors on medical expenditures. Results: Among the 5,160 patients newly diagnosed with CRC, 99.6% of patients had chemotherapy; 32.6% had biologics; and 85.6% had other pharmaceuticals (excluding the chemotherapy and biologics of interest). The average annualized per patient cost of CRC treatment was $97,400 and consisted of chemotherapy ($17,500), biologics ($30,400), other pharmaceuticals ($2,300), inpatient treatment ($26,300), and outpatient treatment ($42,900). From first line only, first and second lines only, and third+ lines, the cost per patient was $70,500, $100,100, and $152,900, respectively. After adjusting for health care inflation, the average treatment cost of CRC patients increased by 73% from 2005 to 2009. Adjusted analyses showed that the higher medical cost for CRC patients was associated with use of new regimens, metastasis, comorbidities, surgery, radiation, insurance plan, age, sex, and region. Conclusion: The health care cost of CRC treatment is increasing significantly over time, which is most likely caused by the use of new regimens, higher chances of surgery and radiation, and occurrence of various comorbidities and metastatic diseases due to increasing survival time.

AB - Background: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). Objective: To identify the patient-related and clinical and treatmentrelated factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. Methods: A longitudinal, retrospective analysis was employed to estimate costs and determinants of CRC treatment in a U.S. claims database for health care services used by commercial patients aged 18 to 64 years, who were diagnosed with CRC between January 1, 2005, and June 30, 2009. Generalized linear regression modeling was used to estimate the influence of demographic, clinical, and treatment factors on medical expenditures. Results: Among the 5,160 patients newly diagnosed with CRC, 99.6% of patients had chemotherapy; 32.6% had biologics; and 85.6% had other pharmaceuticals (excluding the chemotherapy and biologics of interest). The average annualized per patient cost of CRC treatment was $97,400 and consisted of chemotherapy ($17,500), biologics ($30,400), other pharmaceuticals ($2,300), inpatient treatment ($26,300), and outpatient treatment ($42,900). From first line only, first and second lines only, and third+ lines, the cost per patient was $70,500, $100,100, and $152,900, respectively. After adjusting for health care inflation, the average treatment cost of CRC patients increased by 73% from 2005 to 2009. Adjusted analyses showed that the higher medical cost for CRC patients was associated with use of new regimens, metastasis, comorbidities, surgery, radiation, insurance plan, age, sex, and region. Conclusion: The health care cost of CRC treatment is increasing significantly over time, which is most likely caused by the use of new regimens, higher chances of surgery and radiation, and occurrence of various comorbidities and metastatic diseases due to increasing survival time.

UR - http://www.scopus.com/inward/record.url?scp=84884164010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884164010&partnerID=8YFLogxK

M3 - Article

C2 - 23806060

AN - SCOPUS:84884164010

VL - 19

SP - 461

EP - 467

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 6

ER -